Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

2012 ◽  
Vol 91 (11) ◽  
pp. 1825-1826 ◽  
Author(s):  
Kyoko Inokura ◽  
Yasushi Onishi ◽  
Kenji Shimosegawa ◽  
Yoko Okitsu ◽  
Yuna Katsuoka ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Acute Promyelocytic Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Cytogenetic Response ◽  
Promyelocytic Leukemia ◽  
Complete Cytogenetic Response

scholarly journals Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

2015 ◽  
Vol 4 (6S) ◽  
pp. 7-11
Author(s):  
Fabio Stagno ◽  
Alessandra Cupri ◽  
Stefania Stella ◽  
Michele Massimino ◽  
Silvia Rita Vitale ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Prognostic Value ◽  
Kinase Inhibitor ◽  
Chronic Phase ◽  
Initial Response ◽  
Cytogenetic Response ◽  
Affected Patient

Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. However, some pts fail to respond or lose their initial response to IM. The European LeukemiaNet (ELN) published recommendations designed to identify patients responding poorly to imatinib. Here we report a case of a suboptimal cytogenetic responder to IM who had a successful response to the second generation tyrosine kinase inhibitor nilotinib (NIL). According to the ELN criteria, CML pts on IM-therapy might show a suboptimal response either because of failure to achieve a CCyR by 12 months of therapy or because of lack of a MMR after 18 months. The prognostic value of these two types of responders might be very different.

Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

2013 ◽  
Vol 13 (7) ◽  
pp. 755-767 ◽  
Author(s):  
Domenico Russo ◽  
Michele Malagola ◽  
Cristina Skert ◽  
Carla Filì ◽  
Cesare Bergonzi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Elderly Patients ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor

scholarly journals Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia

2019 ◽  
Vol 4 (1-2) ◽  
pp. 41-45 ◽  
Author(s):  
Takeo Koshida ◽  
Sylvia Wu ◽  
Hitoshi Suzuki ◽  
Rimda Wanchoo ◽  
Vanesa Bijol ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Tyrosine Kinase Inhibitors ◽  
Thrombotic Microangiopathy ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Kidney Biopsy ◽  
Kinase Inhibitor ◽  
Target Effect

Dasatinib is the second-generation tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. Proteinuria has been reported with this agent. We describe two kidney biopsy–proven cases of dasatinib-induced thrombotic microangiopathy that responded to stoppage of dasatinib and using an alternate tyrosine kinase inhibitor. Certain specific tyrosine kinase inhibitors lead to endothelial injury and renal-limited thrombotic microangiopathy. Hematologists and nephrologists need to be familiar with this off-target effect of dasatinib.

Sign in / Sign up

Export Citation Format

Share Document